The 1% threshold for PD-L1 positivity in NSCLC is of particular importance considering that several clinical trials have demonstrated that it is associated with clinical benefit to anti-PD-1/PD-L1 therapies in the perioperative, neoadjuvant and adjuvant settings [5, 10, 28]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.